Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Increased infiltration and tolerised antigen-specific CD8+ TEM cells in tumor but not peripheral blood have no impact on survival of HCMV+ glioblastoma patients.
Bahador M, Gras Navarro A, Rahman MA, Dominguez-Valentin M, Sarowar S, Ulvestad E, Njølstad G, Lie SA, Kristoffersen EK, Bratland E, Chekenya M. Bahador M, et al. Among authors: rahman ma. Oncoimmunology. 2017 Jun 5;6(8):e1336272. doi: 10.1080/2162402X.2017.1336272. eCollection 2017. Oncoimmunology. 2017. PMID: 28919997 Free PMC article.
Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors-Human Leukocyte Antigen Ligand Mismatch and Activation Receptor-Ligand Interactions.
Haspels HN, Rahman MA, Joseph JV, Gras Navarro A, Chekenya M. Haspels HN, et al. Among authors: rahman ma. Front Immunol. 2018 Jun 18;9:1345. doi: 10.3389/fimmu.2018.01345. eCollection 2018. Front Immunol. 2018. PMID: 29967607 Free PMC article.
Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival.
Gras Navarro A, Espedal H, Joseph JV, Trachsel-Moncho L, Bahador M, Gjertsen BT, Kristoffersen EK, Simonsen A, Miletic H, Enger PØ, Rahman MA, Chekenya M. Gras Navarro A, et al. Among authors: rahman ma. Cancers (Basel). 2019 Jul 17;11(7):996. doi: 10.3390/cancers11070996. Cancers (Basel). 2019. PMID: 31319548 Free PMC article.
Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.
Rahman MA, Gras Navarro A, Brekke J, Engelsen A, Bindesbøll C, Sarowar S, Bahador M, Bifulco E, Goplen D, Waha A, Lie SA, Gjertsen BT, Selheim F, Enger PØ, Simonsen A, Chekenya M. Rahman MA, et al. Br J Cancer. 2019 Oct;121(7):545-555. doi: 10.1038/s41416-019-0551-1. Epub 2019 Aug 15. Br J Cancer. 2019. PMID: 31413318 Free PMC article.
Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study.
Rahman MA, Brekke J, Arnesen V, Hannisdal MH, Navarro AG, Waha A, Herfindal L, Rygh CB, Bratland E, Brandal P, Haasz J, Oltedal L, Miletic H, Lundervold A, Lie SA, Goplen D, Chekenya M. Rahman MA, et al. Immun Inflamm Dis. 2020 Sep;8(3):342-359. doi: 10.1002/iid3.315. Epub 2020 Jun 24. Immun Inflamm Dis. 2020. PMID: 32578964 Free PMC article. Clinical Trial.
Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma.
Schneider M, Vollmer L, Potthoff AL, Ravi VM, Evert BO, Rahman MA, Sarowar S, Kueckelhaus J, Will P, Zurhorst D, Joseph K, Maier JP, Neidert N, d'Errico P, Meyer-Luehmann M, Hofmann UG, Dolf A, Salomoni P, Güresir E, Enger PØ, Chekenya M, Pietsch T, Schuss P, Schnell O, Westhoff MA, Beck J, Vatter H, Waha A, Herrlinger U, Heiland DH. Schneider M, et al. Among authors: rahman ma. Neuro Oncol. 2021 Nov 2;23(11):1885-1897. doi: 10.1093/neuonc/noab092. Neuro Oncol. 2021. PMID: 33864086 Free PMC article.
2,123 results